Cargando…

PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation

PURPOSE: The inhibition of immune checkpoints such as programmed cell death ligand-1 (PD-L1/CD274) with antibodies is providing novel opportunities to expose cancer cells to the immune system. Antibody based checkpoint blockade can, however, result in serious autoimmune complications because normal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pacheco-Torres, Jesus, Penet, Marie-France, Krishnamachary, Balaji, Mironchik, Yelena, Chen, Zhihang, Bhujwalla, Zaver M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947807/ https://www.ncbi.nlm.nih.gov/pubmed/33718115 http://dx.doi.org/10.3389/fonc.2020.614365

Ejemplares similares

The PD-L1 metabolic interactome intersects with choline metabolism and inflammation
por: Pacheco-Torres, Jesus, et al.
Publicado: (2021)

VEGF Overexpression Significantly Increases Nanoparticle-Mediated siRNA Delivery and Target-Gene Downregulation
por: Tan, Shanshan, et al.
Publicado: (2022)

Acid-degradable Dextran as an Image Guided siRNA Carrier for COX-2 Downregulation
por: Chen, Zhihang, et al.
Publicado: (2018)

PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model
por: Jin, Jiefu, et al.
Publicado: (2022)

Degradable Dextran Nanopolymer as a Carrier for Choline Kinase (ChoK) siRNA Cancer Therapy
por: Chen, Zhihang, et al.
Publicado: (2016)

Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft
por: Bharti, Santosh K., et al.
Publicado: (2018)

Ascites Volumes and the Ovarian Cancer Microenvironment
por: Penet, Marie-France, et al.
Publicado: (2018)

Hypoxia theranostics of a human prostate cancer xenograft and the resulting effects on the tumor microenvironment
por: Krishnamachary, Balaji, et al.
Publicado: (2020)

Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer
por: Krishnamachary, Balaji, et al.
Publicado: (2012)

Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism
por: Penet, Marie-France, et al.
Publicado: (2016)

Phototheranostics of CD44-positive cell populations in triple negative breast cancer
por: Jin, Jiefu, et al.
Publicado: (2016)

Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts
por: Krishnamachary, Balaji, et al.
Publicado: (2017)

Combining Optical Reporter Proteins with Different Half-lives to Detect Temporal Evolution of Hypoxia and Reoxygenation in Tumors
por: Danhier, Pierre, et al.
Publicado: (2015)

COX-2 in cancer: Gordian knot or Achilles heel?
por: Stasinopoulos, Ioannis, et al.
Publicado: (2013)

Hypoxia Inducible Factors Modify Collagen I Fibers in MDA-MB-231 Triple Negative Breast Cancer Xenografts()()
por: Goggins, Eibhlin, et al.
Publicado: (2017)

Reprogramming of VEGF-mediated extracellular matrix changes through autocrine signaling
por: Goggins, Eibhlin, et al.
Publicado: (2023)

HIF and COX-2 expression in triple negative breast cancer cells with hypoxia and 5-fluorouracil
por: Mori, Noriko, et al.
Publicado: (2020)

Evaluating near‐infrared photoimmunotherapy for targeting fibroblast activation protein‐α expressing cells in vitro and in vivo
por: Jin, Jiefu, et al.
Publicado: (2022)

Biomimetic Nanoparticles Camouflaged in Cancer Cell Membranes and Their Applications in Cancer Theranostics
por: Jin, Jiefu, et al.
Publicado: (2020)

HIF isoforms have divergent effects on invasion, metastasis, metabolism and formation of lipid droplets
por: Shah, Tariq, et al.
Publicado: (2015)

Functional roles of FAP-α in metabolism, migration and invasion of human cancer cells
por: Mori, Noriko, et al.
Publicado: (2023)

Brain metabolites in cholinergic and glutamatergic pathways are altered by pancreatic cancer cachexia
por: Winnard, Paul T., et al.
Publicado: (2020)

Hypoxia Patterns in Primary and Metastatic Prostate Cancer Environments()
por: Bharti, Santosh Kumar, et al.
Publicado: (2019)

Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer
por: Luo, Xin, et al.
Publicado: (2017)

Pd-Based Hybrid Nanoparticles As Multimodal Theranostic Nanomedicine
por: Bellissima, Alberto, et al.
Publicado: (2023)

Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis
por: Gu, Zikuan, et al.
Publicado: (2022)

Water and Collagen Content Are High in Pancreatic Cancer: Implications for Quantitative Metabolic Imaging
por: Penet, Marie-France, et al.
Publicado: (2021)

Highlight report: Role of PD-L1 in never-smokers
por: Albrecht, Wiebke
Publicado: (2019)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer
por: Sun, Zhenliang, et al.
Publicado: (2018)

Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment
por: Yu, Xin, et al.
Publicado: (2022)

siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model
por: Jung, Jae Yun, et al.
Publicado: (2021)

Targeted Molecular Construct for Bioorthogonal Theranostics of PD-L1-Expressing Cancer Cells
por: Chow, Shiao Y., et al.
Publicado: (2022)

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
por: Moon, Yujeong, et al.
Publicado: (2022)

Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells
por: Camorani, Simona, et al.
Publicado: (2022)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Phototheranostics of Splenic Myeloid-Derived Suppressor Cells and Its Impact on Spleen Metabolism in Tumor-Bearing Mice
por: Barnett, James D., et al.
Publicado: (2022)

Breast cancer cell adhesome and degradome interact to drive metastasis
por: Rizwan, Asif, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_76sa1v9vle91219671dgso4i55